Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyBrigitta G. Baumert, Roger Stupp, Monika E. Hegi et al.|The Lancet Oncology|2016Cited by 504
Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia.Ilse Schwarzinger, Peter Bettelheim, Ursula Köller et al.|Journal of Clinical Oncology|1990Cited by 96
Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)Matthias Preusser, Wolfgang Wick, Antonio Silvani et al.|Neuro-Oncology|2021Cited by 81
Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningiomaJulia Furtner, Matthias Preusser, Veronika Schöpf et al.|Neuro-Oncology|2015Cited by 67
Emergency intubation with the Combitube in a case of severe facial burnA Wagner, Michael Frass, Martin Roeggla et al.|The American Journal of Emergency Medicine|1995Cited by 16